Showing results (191-200 of 293) with videos related to
Sort By:
Pageof 30
Cancer Chemotherapy and Pharmacology|February 4, 2010
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumorsBrian S Choi, Dona B Alberti, William R Schelman, et al.Pediatric Blood & Cancer|July 27, 2010
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group studyOrren Beaty, Stacey Berg, Susan Blaney, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsRamesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.Molecular and Cellular Biology|August 3, 2011
MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxiaUlrike Bruning, Luca Cerone, Zoltan Neufeld, et al.Cancer Chemotherapy and Pharmacology|September 19, 2020
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration markerAnand Joshi, Jianxia Guo, Julianne L Holleran, et al.Arthritis & Rheumatology (Hoboken, N.J.)|September 24, 2020
A Novel RELA Truncating Mutation in a Familial Behçet's Disease-like Mucocutaneous Ulcerative ConditionFahd Adeeb, Emma R Dorris, Niamh E Morgan, et al.JCO Precision Oncology|February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid TumorsYiduo Hu, Azeet Narayan, Yunshan Xu, et al.Cancer Chemotherapy and Pharmacology|August 2, 2008
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinomaJoanna M Brell, Smitha S Krishnamurthi, Milind Javle, et al.Gynecologic Oncology|November 4, 2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaAndrea E Wahner Hendrickson, Ann L Oberg, Gretchen Glaser, et al.Proceedings of the National Academy of Sciences of the United States of America|October 23, 2013
Regulation of IL-1β-induced NF-κB by hydroxylases links key hypoxic and inflammatory signaling pathwaysCarsten C Scholz, Miguel A S Cavadas, Murtaza M Tambuwala, et al.Pageof 30